An Executed Plan to Combat COVID-19 in the United States
- PMID: 36333051
- PMCID: PMC9276922
- DOI: 10.1016/j.aan.2022.07.002
An Executed Plan to Combat COVID-19 in the United States
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019. To date, this coronavirus is responsible for greater than 90 million cases in the United States and more than 1 million confirmed deaths. When this virus came to the United States, testing was unorganized, no effective treatments were known, and no vaccines had been discovered. A plan to correct these deficiencies through cooperative science and efficient clinical trials was implemented to combat this novel virus. This plan developed efficient and inexpensive tests, highly effective medicines to treat and prevent disease progression, and vaccines to immunize the population.
Keywords: Antivirals; COVID screening; COVID-19; Convalescent plasma; Monoclonal antibodies; Pandemic; SARS-CoV-2; Vaccine.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The author has nothing to disclose.
References
-
- https://www.cdc.gov/coronavirus/2019-ncov/index.html Available at:
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous